MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
-$417K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Net income (loss) and comprehens...
    • Prepaid expenses and other asset...
    • Accounts payable and accrued exp...
    • Others
Negative Cash Flow Breakdown
    • Accounts receivable
    • Change in fair value of warrant ...
    • Right-of-use assets and lease li...
    • Payments for taxes related to ne...
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income (loss) and comprehensive income (loss)
452
-6,344
-9,784
-15,778
Depreciation and amortization
0
120
19
56
Loss on disposal of property and equipment
-
-
-185
-
Change in fair value of warrant liability
-220
-2,674
-831
2,119
Change in fair value of ppas
0
-273
406
-
Commitment fee under sepa
-
-
282
-
Financing costs related to ppas
-
-
742
-
Stock-based compensation
619
956
1,120
1,292
Accounts receivable
2,000
-
-
-
Prepaid expenses and other assets
-418
237
-455
-1,056
Accounts payable and accrued expenses
18
3,069
-747
1,016
Accounts payable and accrued expenses - related parties
300
-
-
0
Right-of-use assets and lease liabilities, net
-6
116
238
358
Net cash used in operating activities
-419
-5,267
-7,915
-9,881
Proceeds from ppas
-
-
7,125
-
Proceeds from issuance of common stock under sepa
0
413
-
-
Payment of financing costs related to issuance of common stock, ppas and sepa
0
289
453
0
Proceeds from issuance of common stock and warrants, net of issuance costs
-
-
0
-
Proceeds from issuance of common stock under employee stock purchase plan
3
-
53
0
Payments for taxes related to net settlement of equity awards
1
14
12
6
Net cash provided by (used in) financing activities
2
110
6,713
-6
Net decrease in cash and cash equivalents
-417
-5,157
-1,202
-9,887
Cash and cash equivalents, beginning of period
1,961
7,118
8,320
49,046
Cash and cash equivalents, end of period
1,544
1,961
7,118
8,320
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofcommon stock under...$3K (-93.62%↓ Y/Y)Net cash provided by(used in) financing...$2K (100.46%↑ Y/Y)Canceled cashflow$1K Net decrease in cashand cash...-$417K (98.65%↑ Y/Y)Canceled cashflow$2K Stock-based compensation$619K (-79.52%↓ Y/Y)Net income (loss)and comprehensive...$452K (101.33%↑ Y/Y)Prepaid expenses andother assets-$418K (-209.14%↓ Y/Y)Accounts payable andaccrued expenses -...$300K Accounts payable andaccrued expenses$18K (-99.29%↓ Y/Y)Payments for taxesrelated to net...$1K (-97.06%↓ Y/Y)Net cash used inoperating activities-$419K (98.62%↑ Y/Y)Canceled cashflow$1,807K Accounts receivable$2,000K Change in fair value ofwarrant liability-$220K (86.10%↑ Y/Y)Right-of-use assets and leaseliabilities, net-$6K (97.62%↑ Y/Y)

BioAtla, Inc. (BCAB)

BioAtla, Inc. (BCAB)